Drug firm Zydus Cadila on Tuesday said that it has got a tentative approval from the US health regulator to market Lorcaserin Hydrochloride Tablets used in the treatment of obesity.
The company has received tentative approval from United States Food and Drug Administration (USFDA) to market the tablets in the strength of 10 mg, Zydus Cadila said in a filing to BSE.
The drug will be manufactured at the Group's formulations manufacturing facility at the Gujarat SEZ.
The group now has 278 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.
Shares of Cadila Healthcare, the listed entity of Zydus Group were today trading at Rs 255.15, down 1.16 per cent on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app